Autoimmune Disease Therapeutics Worldwide: Markets & Developments

SUMMARY

In the next five years, new therapeutic approaches will drive the market forautoimmune disorder treatments to grow at a rate of over 15%, to a value of over$21 billion by 2006. The third largest category of illness in the industrializedworld—behind heart disease and cancer—autoimmune disease is now thefocus of increased research funding, leading to the development of highlysuccessful products.

And Theta' s new study, Autoimmune Disease Therapeutics Worldwide: Markets& Developments will answer your key market and R&D questions:

• What new treatments have already reached market? Are in development?
• What are the current and projected market sizes and shares for thetreatments for each of these disorders?
• Which companies are developing new treatments? When will they reach themarket? Will they be commerically successful?
• How is recent legislation and funding impacting R&D for thesedisorders?

Autoimmune Disease Therapeutics Worldwide covers the range of disorders,including:

• Rheumatoid arthritis   
• Systemic lupus erythematosus
• Inflammatory bowel disease
• Psoriasis
• Multiple sclerosis
• Thyroid disease
• Sjogren' s syndrome
• Myasthenia gravis.

Illustrated with detailed tables and full-color charts, Autoimmune DiseaseTherapeutics Worldwide cuts through the mass of raw data and gives you thevalue-added analysis to make the right decisions in this highly competitivemarket. Order your copy today!

TABLE OF CONTENTS

Table of Contents

1 Executive Summary

1.1 Scope and Objectives of Reports

1.2 Methodology

1.3 The Emerging World Market for Autoimmune Diseases

1.4 Market Size and Forecast

1.5 Competitor Market Summary

2 Introduction and Overview

2.1 Autoimmunity

2.2 Components of the Immune System

2.2.1 Humoral Immunity

2.2.2 Cell-mediated Immunity

2.3 Types of Autoimmune Diseases

2.3.1 Reclassification of Autoimmune Diseases

2.4 Pathology of Autoimmune Disease

2.5 Prevalence and Demographics of Autoimmune Disease

2.5.1 Higher Prevalence Among Women

3 Issues and Trends in Autoimmune Disease Management

3.1 Women' s Health Issues

3.2 Regulatory and Legislative Actions

3.3 Costs of Treatment

3.4 Genes and the Immune System

3.5 Stem Cell Research

3.5.1 Rebooting

4 Rheumatoid Arthritis

4.1 Pathology of Rheumatoid Arthritis

4.2 Risk Factors for Rheumatoid Arthritis

4.3 Prevalence of Rheumatoid Arthritis

4.4 Diagnostics for Rheumatoid Arthritis

4.4.1 Blood Tests

4.4.2 Radiography (X-Rays)

4.4.3 Other Diagnostic Techniques

4.5 Current Treatments for Rheumatoid Arthritis

4.5.1 Aspirin and Traditional NSAIDs

4.5.2 COX-2 Inhibitors

4.5.3 Corticosteroids

4.5.4 Disease-Modifying Antirheumatic Drugs (DMARDs)

4.5.5 Tumor Necrosis Factor (TNF) Inhibitors

4.5.6 Interleukin 1 Inhibitor

4.5.7 Surgical Treatments

4.6 Treatments in Development for Rheumatoid Arthritis

4.7 Market Analysis for Rheumatoid Arthritis

4.7.1 United States

4.7.2 Europe

4.7.3 Japan

4.7.4 Rest of the World

4.8 Competitor Analysis for Rheumatoid Arthritis

5 Systemic Lupus Erythematosus

5.1 Pathology of Systemic Lupus Erythematosus

5.2 Risk Factors for Systemic Lupus Erythematosus

5.3 Prevalence of Systemic Lupus Erythematosus

5.4 Diagnostics for Systemic Lupus Erythematosus

5.5 Current Treatments for Systemic Lupus Erythematosus

5.5.1 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 5.5.2 Corticosteroids

5.5.3 Disease-Modifying Antirheumatic Drugs (DMARDs)

5.6 Treatments in Development for Systemic Lupus Erythematosus

5.7 Market Analysis for Systemic Lupus Erythematosus

5.7.1 United States

5.7.2 Europe

5.7.3 Japan

5.7.4 Rest of the World

5.8 Competitor Analysis for Systemic Lupus Erythematosus

6 Inflammatory Bowel Disease

6.1 Pathology of Inflammatory Bowel Disease

6.1.1 Ulcerative Colitis

6.1.2 Crohn' s Disease

6.2 Risk Factors for Inflammatory Bowel Disease

6.3 Prevalence of Inflammatory Bowel Disease

6.4 Diagnostics for Inflammatory Bowel Disease

6.5 Current Treatments for Inflammatory Bowel Disease

6.5.1 Mesalamine and Sulfasalazine

6.5.2 Corticosteroids

6.5.3 Disease-Modifying Antirheumatic Drugs (DMARDs)

6.5.4 Antibiotics

6.5.5 Tumor Necrosis Factor (TNF) Inhibitors

6.5.6 Surgical Treatments

6.6 Treatments in Development for Inflammatory Bowel Disease

6.7 Market Analysis for Inflammatory Bowel Disease

6.7.1 United States

6.7.2 Europe

6.7.3 Japan

6.7.4 Rest of the World

6.8 Competitor Analysis for Inflammatory Bowel Disease

7 Psoriasis

7.1 Pathology of Psoriasis

7.1.1 Types of Psoriasis

7.2 Risk Factors for Psoriasis

7.3 Prevalence of Psoriasis

7.5 Current Treatments for Psoriasis

7.5.1 Topical Medications

7.5.2 Phototherapy

7.5.3 Systemic Medications

7.6 Treatments in Development for Psoriasis

7.7 Market Analysis for Psoriasis

7.7.1 United States

7.7.2 Europe

7.7.3 Japan

7.7.4 Rest of the World

7.8 Competitor Analysis for Psoriasis

8 Multiple Sclerosis

8.1 Pathology of Multiple Sclerosis

8.1.1 Types of Multiple Sclerosis

8.2 Risk Factors for Multiple Sclerosis

8.2.1 Infection

8.2.2 Genetic Factors

8.3 Prevalence of Multiple Sclerosis

8.4 Diagnostics for Multiple Sclerosis

8.5 Current Treatments for Multiple Sclerosis

8.5.1 Symptomatic Treatments

8.5.2 Causative Treatments

8.6 Treatments in Development for Multiple Sclerosis

8.7 Market Analysis for Multiple Sclerosis

8.7.1 United States

8.7.2 Europe

8.7.3 Japan

8.7.4 Rest of the World

8.8 Competitor Analysis for Multiple Sclerosis

9 Autoimmune Thyroid Disease

9.1 Pathology of Autoimmune Thyroid Disease

9.1.1 Types of Autoimmune Thyroid Disease

9.2 Risk Factors for Autoimmune Thyroid Disease

9.3 Prevalence of Autoimmune Thyroid Disease

9.4 Diagnostics for Autoimmune Thyroid Disease

9.5 Current Treatments for Autoimmune Thyroid Disease

9.6 Treatments in Development for Autoimmune Thyroid Disease

9.7 Market Analysis for Autoimmune Thyroid Disease

9.7.1 United States

9.7.2 Europe

9.7.3 Japan

9.7.4 Rest of the World

9.8 Competitor Analysis for Autoimmune Thyroid Disease

10 Sjogren' s Syndrome

10.1 Pathology of Sjogren' s Syndrome

10.2 Risk Factors for Sjogren' s Syndrome

10.3 Prevalence of Sjogren' s Syndrome

10.4 Diagnostics for Sjogren' s Syndrome

10.5 Current Treatments for Sjogren' s Syndrome

10.6 Treatments in Development for Sjogren' s Syndrome

10.7 Market Analysis for Sjogren' s Syndrome

10.7.1 United States

10.7.2 Europe

10.7.3 Japan

10.7.4 Rest of the World

10.8 Competitor Analysis for Sjogren' s Syndrome

11 Myasthenia Gravis

11.1 Pathology of Myasthenia Gravis

11.2 Risk Factors for Myasthenia Gravis

11.3 Prevalence of Myasthenia Gravis

11.4 Diagnostics for Myasthenia Gravis

11.4.1 Edrophonium Chloride (Tensilon) Test

11.4.2 Neostigmine Test

11.4.3 Antibodies Against Acetylcholine Receptor (AChR)

11.4.4 Electromyography Repetitive Nerve Stimulation (RNS)

11.4.5 Single Fiber Electromyogram (SFEMG)

11.5 Current Treatments for Myasthenia Gravis

11.5.1 Cholinesterase Inhibitors

11.5.2 Corticosteroids

11.5.3 Immunosuppressants

11.5.4 Plasmapheresis

11.5.5 Thymectomy

11.6 Treatments in Development for Myasthenia Gravis

11.7 Market Analysis for Myasthenia Gravis

11.7.1 United States

11.7.2 Europe

11.7.3 Japan

11.7.4 Rest of the World

11.8 Competitor Analysis for Myasthenia Gravis

12 Company Profiles

12.1 Abbott Laboratories

12.2 Abgenix, Inc.

12.3 Aventis Pharma AG

12.4 Berlex Laboratories, Inc.

12.5 Biogen, Inc.

12.6 Bristol-Myers Squibb Co.

12.7 Corixa Corp.

12.8 Elan Corporation, plc

12.9 Eli Lilly & Co.

12.10 Forest Laboratories, Inc.

12.11 Genelabs Technologies, Inc.

12.12 Genentech, Inc.

12.13 GlaxoSmithKline plc

12.14 ICN Pharmaceuticals, Inc.

12.15 Immune Response Corp.

12.16 Immunex Corp.

12.17 King Pharmaceuticals (Jones Pharma, Inc.)

12.18 LaJolla Pharmaceutical Co.

12.19 MGI Pharma, Inc.

12.20 Merck & Co., Inc.

12.21 Novartis Pharmaceuticals Corp.

12.22 Pharmacia Corp.

12.23 Roche Laboratories, Inc.

12.24 Salix Pharmaceuticals, Ltd.

12.25 Sanofi-Synthelabo SA

12.26 Schering-Plough Corp.

12.27 Serono SA

12.28 ZymoGenetics, Inc.

13 Company Directory

List of Tables

• Table 1-1 Total World Market Size and Growth of Autoimmune DiseaseTherapeutics 1996, 2000, 2006
• Table 1-2 World Autoimmune Disease Market Shares by Disease Area 1996,2000, 2006
• Table 1-3 Competitor Total World Market Shares 2000
• Table 2-1 Characteristics of Immunoglobulins
• Table 2-2 Theories of Causation for Autoimmune Diseases
• Table 2-3 Prevalence of Autoimmune Diseases by Type and Geographic Region2000
• Table 2-4 Prevalence of Autoimmune Diseases by Type and Country 2000
• Table 2-5 Female:Male Ratios in Autoimmune Disease Risk
• Table 4-1 Prevalence, Incidence, and Mortality of Rheumatoid Arthritis byGeographic Region 2000
• Table 4-2 Prevalence, Incidence, and Mortality of Rheumatoid Arthritis byCountry 2000
• Table 4-3 NSAIDs Used in RA Treatment
• Table 4-4 Therapeutics in Development for Rheumatoid Arthritis Table 4-5Total World Market Size and Growth of Rheumatoid
• Arthritis Drugs 1996, 2000, 2006
• Table 4-6 Total World Market Size of Rheumatoid Arthritis Drugs byGeographic Region 1996, 2000, 2006
• Table 4-7 Geographic Market Shares of Rheumatoid Arthritis Drugs 2000
• Table 4-8 Geographic Market Shares of Rheumatoid Arthritis Drugs 2006
• Table 4-9 Market Size and Growth in United States of Rheumatoid ArthritisDrugs 1996-2006
• Table 4-10 Market Size and Growth in Europe* of Rheumatoid Arthritis Drugs1996-2006
• Table 4-11 Market Size and Growth in Japan of Rheumatoid Arthritis Drugs1996-2006
• Table 4-12 Market Size and Growth in the Rest of the World of RheumatoidArthritis Drugs 1996-2006
• Table 4-13 Competitor Revenues and World Market Shares for RheumatoidArthritis Drugs 2000
• Table 5-1 Prevalence, Incidence, and Mortality of Systemic LupusErythematosus by Geographic Region 2000
• Table 5-2 Prevalence, Incidence, and Mortality of Systemic LupusErythematosus by Country 2000
• Table 5-3 NSAIDs Used in Systemic Lupus Erythematosus Treatment Table 5-4Therapeutics in Development for Systemic Lupus Erythematosus
• Table 5-5 Total World Market Size and Growth of Systemic LupusErythematosus Drugs 1996, 2000, 2006
• Table 5-6 Total World Market Size of Systemic Lupus Erythematosus Drugs byGeographic Region 1996, 2000, 2006
• Table 5-7 Geographic Market Shares of Systemic Lupus Erythematosus Drugs2000
• Table 5-8 Geographic Market Shares of Systemic Lupus Erythematosus Drugs2006
• Table 5-9 Market Size and Growth in United States of Systemic LupusErythematosus Drugs 1996-2006
• Table 5-10 Market Size and Growth in Europe* of Systemic LupusErythematosus Drugs 1996-2006
• Table 5-11 Market Size and Growth in Japan of Systemic Lupus ErythematosusDrugs 1996-2006
• Table 5-12 Market Size and Growth in the Rest of the World of SystemicLupus Erythematosus Drugs 1996-2006
• Table 5-13 Competitor Revenues and World Market Shares for Systemic LupusErythematosus Drugs 2000
• Table 6-1 Prevalence and Incidence of Inflammatory Bowel Disease byGeographic Region 2000
• Table 6-2 Prevalence and Incidence of Inflammatory Bowel Disease byCountry 2000
• Table 6-3 Therapeutics in Development for Inflammatory Bowel Disease
• Table 6-4 Total World Market Size and Growth of Inflammatory Bowel DiseaseDrugs 1996, 2000, 2006
• Table 6-5 Total World Market Size of Inflammatory Bowel Disease Drugs byGeographic Region 1996, 2000, 2006
• Table 6-6 Geographic Market Shares of Inflammatory Bowel Disease Drugs2000
• Table 6-7 Geographic Market Shares of Inflammatory Bowel Disease Drugs2006
• Table 6-8 Market Size and Growth in United States of Inflammatory BowelDisease Drugs 1996-2006
• Table 6-9 Market Size and Growth in Europe* of Inflammatory Bowel DiseaseDrugs 1996-2006
• Table 6-10 Market Size and Growth in Japan of Inflammatory Bowel DiseaseDrugs 1996-2006
• Table 6-11 Market Size and Growth in the Rest of the World of InflammatoryBowel Disease Drugs 1996-2006
• Table 6-12 Competitor Revenues and World Market Shares for InflammatoryBowel Disease Drugs 2000
• Table 7-1 Prevalence, Incidence, and Mortality of Psoriasis by GeographicRegion 2000
• Table 7-2 Prevalence, Incidence, and Mortality of Psoriasis by Country2000
• Table 7-3 Topical Corticosteroids for Psoriasis
• Table 7-4 Therapeutics in Development for Psoriasis
• Table 7-5 Total World Market Size and Growth of Psoriasis Drugs 1996,2000, 2006
• Table 7-6 Total World Market Size of Psoriasis Drugs by Geographic Region1996, 2000, 2006
• Table 7-7 Geographic Market Shares of Psoriasis Drugs 2000 Table 7-8Geographic Market Shares of Psoriasis Drugs 2006 Table 7-9 Market Size andGrowth in United States of Psoriasis Drugs 1996-2006
• Table 7-10 Market Size and Growth in Europe* of Psoriasis Drugs 1996-2006
• Table 7-11 Market Size and Growth in Japan of Psoriasis Drugs 1996-2006
• Table 7-12 Market Size and Growth in the Rest of the World of PsoriasisDrugs 1996-2006
• Table 7-13 Competitor Revenues and World Market Shares for Psoriasis Drugs2000
• Table 8-1 Prevalence, Incidence, and Mortality of Multiple Sclerosis byGeographic Region 2000
• Table 8-2 Prevalence, Incidence, and Mortality of Multiple Sclerosis byCountry 2000
• Table 8-3 Therapeutics in Development for Multiple Sclerosis Table 8-4Total World Market Size and Growth of Multiple Sclerosis Drugs 1996, 2000,2006
• Table 8-5 Total World Market Size of Multiple Sclerosis Drugs byGeographic Region 1996, 2000, 2006
• Table 8-6 Geographic Market Shares of Multiple Sclerosis Drugs 2000
• Table 8-7 Geographic Market Shares of Multiple Sclerosis Drugs 2006
• Table 8-8 Market Size and Growth in United States of Multiple SclerosisDrugs 1996-2006
• Table 8-9 Market Size and Growth in Europe* of Multiple Sclerosis Drugs1996-2006
• Table 8-10 Market Size and Growth in Japan of Multiple Sclerosis Drugs1996-2006
• Table 8-11 Market Size and Growth in the Rest of the World of MultipleSclerosis Drugs 1996-2006
• Table 8-12 Competitor Revenues and World Market Shares for MulitpleSclerosis Drugs 2000
• Table 9-1 Prevalence and Incidence of Autoimmune Thyroid Disease byGeographic Region 2000
• Table 9-2 Prevalence and Incidence of Autoimmune Thyroid Disease byCountry 2000
• Table 9-3 Diagnostic Findings of Hashimoto' s Thyroiditis
• Table 9-4 Total World Market Size and Growth of Autoimmune Thyroid DiseaseDrugs 1996, 2000, 2006
• Table 9-5 Total World Market Size of Autoimmune Thyroid Disease Drugs byGeographic Region 1996, 2000, 2006
• Table 9-6 Geographic Market Shares of Autoimmune Thyroid Disease Drugs2000
• Table 9-7 Geographic Market Shares of Autoimmune Thyroid Disease Drugs2006
• Table 9-8 Market Size and Growth in United States of Autoimmune ThyroidDisease Drugs 1996-2006
• Table 9-9 Market Size and Growth in Europe* of Autoimmune Thyroid DiseaseDrugs 1996-2006
• Table 9-10 Market Size and Growth in Japan of Autoimmune Thyroid DiseaseDrugs 1996-2006
• Table 9-11 Market Size and Growth in the Rest of the World of AutoimmuneThyroid Disease Drugs 1996-2006
• Table 9-12 Competitor Revenues and World Market Shares for AutoimmuneThyroid Disease Drugs 2000
• Table 10-1 Prevalence of Sjogren' s Syndrome by Geographic Region 2000
• Table 10-2 Prevalence of Sjogren' s Syndrome by Country 2000
• Table 10-3 Total World Market Size and Growth of Sjogren' s Syndrome Drugs1996, 2000, 2006
• Table 10-4 Total World Market Size of Sjogren' s Syndrome Drugs byGeographic Region 1996, 2000, 2006
• Table 10-5 Geographic Market Shares of Sjogren' s Syndrome Drugs 2000
• Table 10-6 Geographic Market Shares of Sjogren' s Syndrome Drugs 2006
• Table 10-7 Market Size and Growth in United States of Sjogren' s SyndromeDrugs 1996-2006
• Table 10-8 Market Size and Growth in Europe* of Sjogren' s Syndrome Drugs1996-2006
• Table 10-9 Market Size and Growth in Japan of Sjogren' s Syndrome Drugs1996-2006
• Table 10-10 Market Size and Growth in the Rest of the World of Sjogren' sSyndrome Drugs 1996-2006
• Table 10-11 Competitor Revenues and World Market Shares for Sjogren' sSyndrome Drugs 2000
• Table 11-1 Prevalence and Incidence of Myasthenia Gravis by GeographicRegion 2000
• Table 11-2 Prevalence and Incidence of Myasthenia Gravis by Country 2000
• Table 11-3 Total World Market Size and Growth of Myasthenia Gravis DiseaseDrugs 1996, 2000, 2006
• Table 11-4 Total World Market Size of Myasthenia Gravis Drugs byGeographic Region 1996, 2000, 2006
• Table 11-5 Geographic Market Shares of Myasthenia Gravis Drugs 2000
• Table 11-6 Geographic Market Shares of Myasthenia Gravis Drugs 2006
• Table 11-7 Market Size and Growth in United States of Myasthenia GravisDrugs 1996-2006
• Table 11-8 Market Size and Growth in Europe* of Myasthenia Gravis Drugs1996-2006
• Table 11-9 Market Size and Growth in Japan of Myasthenia Gravis Drugs1996-2006
• Table 11-10 Market Size and Growth in the Rest of the World of MyastheniaGravis Drugs 1996-2006
• Table 11-11 Competitor Revenues and World Market Shares for MyastheniaGravis Drugs 2000
• Table 12-1 Company Market Involvement by Autoimmune Disease Area